SyntekaBio Inc
SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, di… Read more
SyntekaBio Inc (226330) - Total Assets
Latest total assets as of September 2025: ₩33.49 Billion KRW
Based on the latest financial reports, SyntekaBio Inc (226330) holds total assets worth ₩33.49 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
SyntekaBio Inc - Total Assets Trend (2017–2024)
This chart illustrates how SyntekaBio Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
SyntekaBio Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
SyntekaBio Inc's total assets of ₩33.49 Billion consist of 28.7% current assets and 71.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 27.6% |
| Accounts Receivable | ₩187.20K | 0.0% |
| Inventory | ₩0.00 | 0.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩450.39 Million | 1.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how SyntekaBio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SyntekaBio Inc's current assets represent 28.7% of total assets in 2024, a decrease from 50.9% in 2017.
- Cash Position: Cash and equivalents constituted 27.6% of total assets in 2024, up from 0.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 20.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 1.0% of total assets.
SyntekaBio Inc Competitors by Total Assets
Key competitors of SyntekaBio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
UCrest Bhd
KLSE:0005
|
Malaysia | RM48.46 Million |
|
Vanfund Urban Investment & Development Co Ltd
SHE:000638
|
China | CN¥265.74 Million |
|
BIT Computer Co. Ltd
KQ:032850
|
Korea | ₩82.38 Billion |
|
ezCaretech Co. LTD
KQ:099750
|
Korea | ₩56.71 Billion |
|
Carelabs Co.Ltd
KQ:263700
|
Korea | ₩105.15 Billion |
|
Shanghai Kingstar Winning Software
SHE:300253
|
China | CN¥8.35 Billion |
|
Longmaster Information Tech
SHE:300288
|
China | CN¥1.33 Billion |
|
B-Soft Co Ltd
SHE:300451
|
China | CN¥5.49 Billion |
SyntekaBio Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - SyntekaBio Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - SyntekaBio Inc is currently not profitable relative to its asset base.
SyntekaBio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.20 | 1.00 | 40.04 |
| Quick Ratio | 0.20 | 1.00 | 40.04 |
| Cash Ratio | 0.00 | 0.97 | 0.00 |
| Working Capital | ₩-15.30 Billion | ₩ -7.67 Million | ₩ 40.50 Billion |
SyntekaBio Inc - Advanced Valuation Insights
This section examines the relationship between SyntekaBio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.46 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -17.4% |
| Total Assets | ₩43.71 Billion |
| Market Capitalization | $28.61 Million USD |
Valuation Analysis
Below Book Valuation: The market values SyntekaBio Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: SyntekaBio Inc's assets decreased by 17.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for SyntekaBio Inc (2017–2024)
The table below shows the annual total assets of SyntekaBio Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩43.71 Billion | -17.39% |
| 2023-12-31 | ₩52.92 Billion | -4.98% |
| 2022-12-31 | ₩55.69 Billion | -17.96% |
| 2021-12-31 | ₩67.88 Billion | +51.59% |
| 2020-12-31 | ₩44.78 Billion | -6.61% |
| 2019-12-31 | ₩47.95 Billion | +296.00% |
| 2018-12-31 | ₩12.11 Billion | +383.70% |
| 2017-12-31 | ₩2.50 Billion | -- |